Vericel Corporation (FRA:ATQP)

Germany flag Germany · Delayed Price · Currency is EUR
30.40
+0.40 (1.33%)
At close: Jan 30, 2026
-47.13%
Market Cap1.53B -44.5%
Revenue (ttm)220.50M +14.1%
Net Income11.15M +268.7%
EPS0.21 +236.5%
Shares Outn/a
PE Ratio137.37
Forward PE87.78
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume28
Open30.40
Previous Close30.00
Day's Range30.40 - 30.40
52-Week Range25.40 - 59.50
Betan/a
RSI43.16
Earnings DateFeb 27, 2026

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1989
Employees 357
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ATQP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements